Clinical Trial Update: Open-Label Extension Study of ASTORIA [Phase 2]

View source ↗

Summary

Open-label extension of ASTORIA in dyskinesias has been terminated in a Phase 2 trial sponsored by Contera Pharma A/S.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesias

Drugs mentioned

• ASTORIA

Snippet

Sponsor: Contera Pharma A/S | Conditions: Dyskinesias | Phase 2 | Status: TERMINATED